國制藥巨頭默沙東（Merck & Co）近日在2016年第52屆美國臨床腫瘤學會（ASCO）年會上公布了PD-1免疫療法Keytruda（pembrolizumab）聯合其他治療方案（包括癌癥疫苗T-vec、dabrafenib+trametinib、低劑量ipilimumab）治療晚期黑色素瘤的3個研究的數據。

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.